The submission of Dapagliflozin by Jiangsu Hansoh Pharma represents a significant competitive move in the SGLT2 inhibitor market. This could disrupt existing market dynamics and necessitate strategic adjustments from established players to maintain their market positions. Regulatory context from FDA (FDA TA — DAPAGLIFLOZIN (ORIG)) supports the near-term read. Assessment grounded in 16 ranked evidence items (10 high-relevance).